Skip to main content

Table 5 Secondary analyses comparing Hospitalizations for musculoskeletal conditions among DMARDs users and non-users before and after the introduction of anti-TNF drugs to the Quebec market

From: Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: a population-based study

 

Exposure duration (days)

Number (Unadjusted rate per 100 patient-yrs)

Hazard ratio

(95 % CI)

 

Total

Median

(Quartile range)

1998–2001

    

DMARDs

1,243,393

365.0 (12.0)

229 (6.72)

1.16 (0.95, 1.41)

Non-users

1,998,164

317.0 (193.0)

362 (6.61)

1.00 (Reference)

2002–2006

    

DMARDs

1,949,824

365.0 (0.0)

289 (5.41)

0.86 (0.73, 1.01)

Non-users

3,270,739

365.0 (169.0)

614 (6.85)

1.00 (Reference)

2007–2011

    

DMARDs

2,785,950

365.0 (0.0)

344 (4.51)

0.71 (0.60, 0.84)

Non-users

3,970,012

296.0 (224.0)

797 (7.33)

1.00 (Reference)

  1. CI confidence interval